P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Ajay K. Nooka,Andrew Yee,Carol Ann Huff,Dan T. Vogl,Maria Gavriatopoulou,Ajai Chari,Philippe Moreau,David Dingli,Craig E. Cole,Sagar Lonial,Meletios A. Dimopoulos,Joshua Richter,Ravi Vij,Sascha A. Tuchman,Marc S. Raab,Noa Biran,David S. Siegel,Paul G. Richardson,Jianjun Liu,Anita Joshi,Jatin P. Shah,Sharon Shacham,Michael Kauffman,Sundar Jagannath +23 more
TL;DR: These analyses support the use of Sel-dex in patients with high-risk cytogenetics and warrant further evaluation of selinexor in combination with other anti-myeloma therapies in high- risk disease.
Journal ArticleDOI
Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.
Nikhil C. Munshi,Hervé Avet-Loiseau,Phil Stephens,Masood A. Shammas,Cheng Li,Leutz Buon,Samir B. Amin,Parantu K. Shah,Benjamin King,Mariateresa Fulciniti,Jagannath Pal,Yu-Tzu Tai,Paul G. Richardson,Stephane Minvielle,Peter J. Campbell,Kenneth C. Anderson,Andrew Futreal +16 more
TL;DR: This is the first study utilizing massively parallel sequencing to investigate the MM genome and provides important insight into the pathogenesis of disease progression and confirms the potential of whole genome sequencing to inform biology of the disease that may affect the therapeutic approach in future.
Journal ArticleDOI
Reversine: A Chemical Probe Providing Insight into Myeloma Biology and Potential Therapeutic Applications.
Douglas W. McMillin,D. Corey Geer,Joseph Negri,Nicholas Mitsiades,Teru Hideshima,Dharminder Chauhan,Yu-Tzu Tai,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson,Constantine S. Mitsiades +10 more
TL;DR: In vitro studies of multiple myeloma cells with reversine suggest that reversine may represent a distinct class of agents with therapeutic potential for specific subset(s) of MM and perhaps other hematologic neoplasias, and supports a broader conclusion that reversal has distinct profiles of molecular effects and anti-MM activity.
Journal ArticleDOI
Defibrotide (DF) for the Treatment of Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Analysis of Response and Survival According to Degree and Type of MOF.
Paul G. Richardson,Robert J. Soiffer,Joseph H. Antin,Zhezhen Jin,Joanne Kurtzberg,Paul L. Martin,David M. Hockenbery,K. F. Murray,Georgia B. Vogelsang,Allen R. Chen,Aparna Krishnan,Nancy A. Kernan,David Avigan,Thomas R. Spitzer,Diane Warren,P. Momtaz,Carolyn Revta,L. J. Wei,Massimo Iacobelli,George B. McDonald,Eva C. Guinan +20 more
TL;DR: DF therapy achieved encouraging CR rates and d+100 survival in pts with MOF in up to three systems complicating VOD post SCT, and clinical benefit was seen even if pts were DD and/or VD, which suggests that earlier intervention with DF may further improve outcome.
Journal ArticleDOI
Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1
Sara Bringhen,Peter M. Voorhees,Torben Plesner,Ulf-Henrik Mellqvist,Brandi Reeves,Pieter Sonneveld,Catriona Byrne,Eva Nordström,Johan Harmenberg,Jakob Obermüller,Paul G. Richardson +10 more
TL;DR: Melflufen and dexamethasone resulted in sustained long-term benefits and no new AEs with 1.5 years of additional follow-up of patients with late-stage, heavily pretreated RRMM who have relapsed on conventional therapy including bortezomib and lenalidomide.